Eyepoint Inc (EYPT) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Eyepoint Inc   (NASDAQ: EYPT)

Eyepoint Inc

Officers & Directors


GEORGE O. ELSTON
Executive Vice President and Chief Financial Officer

YE LIU
Director

JAY S. DUKER
President, Chief Executive Officer and Director (Principal Executive Officer)

JOHN LANDIS
Director

KAREN ZADEREJ
Director

NANCY LURKER
Executive Vice Chair of the Board of Directors

STUART DUTY
Director

GO RAN ANDO
Chair of the Board of Directors

ANTHONY P. ADAMIS
Director

WENDY DICICCO
Director

DAVID R. GUYER
Director ,

Eyepoint Inc currently has 214 employees.

  News about Eyepoint Inc Key Personnel

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EyePoint Pharmaceuticals: Strategic Growth and Promising Developments in OphthalmologyIn an era where the pharmaceutical industry faces rigorous competition and rapid advancements, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is making noteworthy progress in its quest to provide innovative solutions for serious retinal diseases. The company’s latest updates reveal a strategic public offering aimed at fueling operational growth, as well as encouraging developments in its clinical trials for groundbreaking therapies.Strong Financial Moves for Sustainable GrowthOn October 29, 2024, EyePoint Pharmaceuticals announced the pricing of an upsized public offering, which reflects its commitment to expanding its ca...

EyePoint Pharmaceuticals Initiates $100 Million Public Offering, Upsizes to $140 Million to Fuel Growth in Retinal Disease Treatments,

EyePoint Pharmaceuticals Expands Growth Horizon with Major Public Offering: Insights and ImplicationsOn October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company focused on innovative therapeutics for retinal diseases, announced its intention to initiate an underwritten public offering of common stock worth $100 million. This strategic move underscores both the company’s commitment to advancing ophthalmic therapies and its proactive approach to bolster its financial foundation amidst previously recorded losses. Strategic Offering OverviewIn the announced public offering, EyePoint plans to issue all shares on its own behalf, indicative of a self-reliant growth strategy. The offe...

EyePoint Pharmaceuticals Grants Inducement Awards Amidst Financial Struggles


By

EyePoint Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of therapies for serious retinal diseases, recently announced the grant of non-statutory stock options under NASDAQ Listing Rule 5635(c)(4) to new employees. This move comes as the company grapples with significant financial challenges, including a cumulative net loss of $100 million during the 12-month period ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -61.76%.
The decision to award inducement grants outside the Company s 2023 Long-Term Incentive Plan sheds light on EyePoint Pharmaceuticals strategic approach towards attracting ...






EYPT Management Effectiveness EYPT Revenue per Employee EYPT Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.